DeuteRx Celebrates 15 Years of Pioneering Drug Discovery Leadership

Chair, President, and CEO Sheila DeWitt, PhD, reflects on company's history of innovation and M&A success

Mar. 31, 2026 at 3:58pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still life featuring a collection of premium laboratory equipment and glassware arranged elegantly on a clean, monochromatic background, symbolizing the scientific rigor and innovative spirit behind DeuteRx's drug discovery platform.DeuteRx's innovative drug discovery platform, built on 15 years of pioneering leadership, has produced multiple successful asset sales and industry recognition for the company's scientific and executive team.Boston Today

DeuteRx, a Boston-based biopharmaceutical company, is celebrating the 15-year tenure of its Chair, President, and CEO, Sheila DeWitt, PhD, a trailblazing leader in the field of deuterium-enabled drug discovery. Under DeWitt's guidance, DeuteRx has advanced multiple drug candidates, completed four landmark M&A transactions, and earned industry recognition for its scientific and executive leadership.

Why it matters

DeuteRx's success highlights the impact that women-led companies can have in driving pharmaceutical innovation and creating value through strategic partnerships. DeWitt's pioneering work with deuterium-enabled chiral switching has the potential to produce improved therapeutics for a range of diseases, from metabolic disorders to cancer and psychiatric conditions.

The details

In 2010, DeWitt invented Deuterium-Enabled Chiral Switching (DECS), a novel strategy to stabilize interconverting stereoisomers in racemic drugs. This technology formed the basis for DeuteRx's R&D platform, leading to the discovery and development of several drug candidates. Over the past 15 years, the company has successfully completed four M&A transactions, selling assets in the areas of metabolic, cancer, and psychiatric disorders to larger pharmaceutical companies.

  • DeuteRx was founded in 2010 to advance the DECS technology.
  • In 2012, Deuteria Pharmaceuticals, the initial company founded to develop DECS, was acquired by Celgene.
  • Between 2018 and 2025, DeuteRx completed three additional M&A transactions, selling drug candidates for metabolic, cancer, and psychiatric disorders.

The players

Sheila DeWitt, PhD

Chair, President, and CEO of DeuteRx, LLC, an industry-recognized life sciences executive and serial entrepreneur with more than 35 years of leadership in pharmaceutical and biotechnology companies.

DeuteRx, LLC

A privately held biopharmaceutical company dedicated to developing differentiated new medicines with improved therapeutic profiles for patients, using its proprietary Deuterium-Enabled Chiral Switching (DECS) technology.

Got photos? Submit your photos here. ›

What they’re saying

“Women's History Month is a time to reflect on the progress that has been made and the work that still lies ahead. I am proud of what the DeuteRx team has accomplished, not only with a commitment to advancing better medicines for patients, but in demonstrating that lean, focused, and value-driven science can compete at the highest levels. I hope our journey inspires and empowers the next generation of women in science, entrepreneurship, and leadership.”

— Sheila DeWitt, PhD, Chair, President & CEO, DeuteRx, LLC

What’s next

DeuteRx is currently advancing programs in spasticity, neuropathic pain, and rare dermatologic conditions, continuing to apply its DECS strategy to create best-in-class therapeutics.

The takeaway

DeuteRx's success under the leadership of Sheila DeWitt, PhD, demonstrates the significant impact that women-led companies can have in driving pharmaceutical innovation and creating value through strategic partnerships. The company's pioneering work with deuterium-enabled chiral switching has the potential to produce improved treatments for a range of diseases.